Invitae reports preliminary FY22 metrics

Preliminary, unaudited financial results and other metrics for 2022: Generated revenue of approximately $516 million in 2022, or about a 12% increase from $460 million in 2021. FY22 consensus $515.61M. Fourth quarter 2022 revenue was approximately $122 million, versus $126 million a year ago, which reflects a decline due to the exited businesses and geographies. Q4 consensus $121.46M. Cash, cash equivalents, restricted cash and marketable securities were greater than $555 million as of December 31, 2022. Our cash burn in the fourth quarter was less than $80 million, which excludes an outflow of approximately $10 million related to realignment and an inflow of approximately $45 million related to the selected assets sale of the RUO kitted solutions. This represents a continued declining trend since the fourth quarter of 2021. Total active healthcare provider accounts of approximately 20,000, an increase of 8% from 2021. Active pharma and commercial partnerships grew to approximately 230, an increase of 29% in 2022, due to revenue growth from lab services, data services to pharmaceutical, health systems and other partners. Total patient population is more than 3.6 million with over 62% available for data sharing.